ClinicalTrials.gg
Active, not recruitingNCT03607370ST812Updated Nov 8, 2023

Timing for Rectal Surgery After Chemoradiotherapy

An interventional study of Surgery after 12 weeks of delay after chemoradiotherapy. in Rectal Cancer, sponsored by National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos. Active, not recruiting at 1 site in Lithuania. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-11-08.

Sponsored by National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 10 months ago, but the record still lists the study as active, not recruiting.
  • Registered 11 months after the study started (first participant enrolled Jul 2017, registered Jun 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Study summary

The aim of this study is to determine whether greater rectal cancer downstaging and regression occurs when surgery is delayed to 12 weeks after completion of radiotherapy/chemotherapy compared to 8 weeks.

Hypothesis: Greater down-staging and tumor regression is observed when surgery is delayed to 12 weeks after completion of chemoradiotherapy compared to 8 weeks.

02

Conditions studied

  • Rectal Cancer

Browse trials for

Keywords

  • Rectal cancer
  • Chemoradiotherapy
  • Surgery
03

In context

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.

This study's enrollment of 142 is above the median of 65 across 1,753 interventional studies indexed under Rectal Neoplasms.

Browse Rectal Neoplasms studies →

Lead sponsor

National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years old
  • (ECOG) 0-1,
  • ' (ASA) score I-III
  • Histological confirmation of adenocarcinoma of rectum
  • T3 or T4 N0, T any N positive cancer on MRI, without on CT scan
  • Undergoing preoperative radiotherapy/ chemotherapy
  • Curative total mesorectal excision intended
  • Written
  • Patients undergoing preoperative radiotherapy should not be excluded

Exclusion criteria

Exclusion Criteria:

  • Patients with distant
  • T1 or T2, N0 cancer on MRI
  • Rectal cancer 12 cm above the dentate line
  • to MRI
  • Patients previously treated of pelvic organ cancer
  • Medical or psychiatric conditions that compromise the patients ability to give
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
142 participants (actual)

Study arms

  • No intervention
    Group 1

    The cancer surgery is practice 8 weeks after neoadjuvant chemoradiotherapy

  • Experimental
    Group 2

    The cancer surgery will be performed in 12 weeks after neoadjuvant chemoradiotherapy

    Procedure: Surgery after 12 weeks of delay after chemoradiotherapy.

Interventions

  • ProcedureSurgery after 12 weeks of delay after chemoradiotherapy.

    Surgery consists oncologic resection of the rectal cancer with total excision of the mesorectum after 12 weeks of delay after the end of chemoradiotherapy.

06

What researchers measure

Primary outcomes

  1. Complete pathologic response assessed by pathologist Dworak scale

    Dworak scale assesses the response: 0. No regression; 1. Predominantly tumor with significant fibrosis and/or vasculopathy; 2. Predominantly fibrosis with scattered tumor cells (slightly recognizable histologically); 3. Only scattered tumor cells in the space of fibrosis with/without acellular mucin; 4. No vital tumor cells detectable

    Time frame: 6 months

Secondary outcomes

  1. Clinical response assessed using MRi

    Rates of clinical response to chemoradiotherapy before surgery, comparison between the two groups

    Time frame: 8 weeks (2 months)

  2. Pathological response assessed by pathologist using Dworak scale

    Dworak scale assesses the response: 0. No regression; 1. Predominantly tumor with significant fibrosis and/or vasculopathy; 2. Predominantly fibrosis with scattered tumor cells (slightly recognizable histologically); 3. Only scattered tumor cells in the space of fibrosis with/without acellular mucin; 4. No vital tumor cells detectable

    Time frame: 6 months

  3. Incidence of Treatment-Emergent Adverse Events as assessed by Clavien-Dindo scale

    Rates of operative morbidity at 30 days, comparison between the two groups. Grade I Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions Allowed therapeutic regimens are: drugs as antiemetics, antipyretics, analgetics, diuretics and electrolytes and physiotherapy. This grade also includes wound infections opened at the bedside. Grade II Requiring pharmacological treatment with drugs other than such allowed for grade I complications. Blood transfusionsand total parenteral nutritionare also included. Grade III Requiring surgical, endoscopic or radiological intervention * IIIa Intervention not under general anesthesia * IIIb Intervention under general anesthesia Grade IV Life-threatening complication (including CNS complications)\* requiring IC/ICU-management * IVa single organ dysfunction (including dialysis) * IVb multiorgan dysfunction

    Time frame: 30 days

  4. Incidence of Mortality assessed by Clavien-Dindo scale

    Rates of operative mortality at 30 days, comparison between the two groups. Grade V Death of a patient

    Time frame: 30 days

  5. Total mesorectal excision (TME) quality assessed by TME completeness scale (by P.Quircke)

    Quality of mesorectum resection assessed by TME completeness scale: 1. Mesorectal resection (MRR)/good/complete: intact mesorectum and smooth mesorectal surface with only minor irregularities; no defects deeper than 5 mm; no coning of the specimen towards the distal margin; and smooth macro-circular resection margin (CRM) on slicing. 2. Intramesorectal resection (IMR)/intermediate/nearly complete: intermediate bulk of the mesorectum with an irregular surface; a defect deeper than 5 mm, and no visible muscularis propria other than inserted levator; intermediate coning; intermediate irregularity of macro-CRM on slicing. 3. Muscularis propria resection (MPR)/poor/incomplete: small bulk of the mesorectum with a very irregular surface; defect down to the muscularis propria; severe coning; severe irregularity of macro-CRM on slicing.

    Time frame: 8-12 weeks

  6. Distant recurrence assessed by CT scan

    Distant recurrence rates, comparison between the two groups

    Time frame: 5 years

  7. Local recurrence assessed by CT scan/MRI/endoscopy

    Local recurrence rates, comparison between the two groups

    Time frame: 5 years

  8. Oncological outcome - overall survival

    Overall survival rates, comparison between the two groups

    Time frame: 5 years

  9. Oncological outcome - disease-free survival

    Disease-free survival rates, comparison between the two groups

    Time frame: 5 years

  10. Radiotherapy skin toxicity assessed by EORTC scale

    Radiotherapy related toxicity rates: skin reactions will be assessed using EORTC radiotherapy toxicity scale: Skin Grade 1 follicular, faint or dull erythema / epilation / dry desquamation / decreased sweating; Grade 2 tender or bright erythema, patchy moist desquamation / moderate edema; Grade 3 confluent, moist desquamation other than skin folds, pitting edema; Grade 4 - ulceration, hemorrhage, necrosis

    Time frame: 5 years

  11. Radiotherapy toxicity assessed by EORTC scale

    Radiotherapy related toxicity rates: gastrointestinal reactions will be assessed using EORTC radiotherapy toxicity scale: Grade 1 increased frequency or change in quality of bowel habits not requiring medication / rectal discomfort not requiring analgesics; Grade 2 diarrhea requiring parasympatholytic drugs (e.g. Lomotil) / mucous discharge not necessitating sanitary pads / rectal or abdominal pain requiring analgesics; Grade 3 diarrhea requiring parenteral support / severe mucous or blood discharge necessitating sanitary pads / abdominal distention (flat plate radiograph demonstrates distended bowel loops); Grade 4 acute or subacute obstruction, fistula or perforation; GI bleeding requiring transfusion; abdominal pain or tenesmus requiring tube decompression or bowel diversion

    Time frame: 5 years

  12. Quality of Life assessed by Low anterior resection syndrome score

    The Low anterior resection syndrome score (LARS) score consists of five items concerning the following: incontinence for flatus, incontinence for liquid stool, frequency of bowel movements, clustering of stools, and urgency. Each symptom of bowel dysfunction is weighed according to its impact on the quality of life. The calculated score ranges from 0 to 42, with a score of 0-20 representing no ARS, a score of 21-29 representing minor ARS, and a score of 30-42 representing major ARS.

    Time frame: 1 year

  13. Immune response assessed

    We have assessed the immune response before chemoradiotherapy and 8 weeks following the treatment. IL1B, IL6, IL8, IL10, IL2R, TNF alfa are assessed and will be correlated with the response to treatment.

    Time frame: 1 year

  14. Urinary catheter removal timing

    All the patients will have there urinary catheters removed on day 1. Some patients will get Urorec (adrenomimetic for prevention of urinary retention). The patients will be randomized 2:1

    Time frame: 3 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Dec 2023, 77 months after the start.

Of 329 non-industry interventional studies with no phase under Rectal Neoplasms, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 78. This study's planned 77 months is above that.

Counting every sponsor, half of 336 studies reached it within 51 months; a quarter within 23 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2018
First posted
Jul 31, 2018
StartActual
Jul 1, 2017
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2025
Last update
Nov 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03607370
Lead sponsor
National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos
Responsible party
Audrius Dulskas (Assoc. profesor, National Cancer Center Affiliate of Vilnius University Hospital Santaros Klinikos) — Principal investigator
First posted
Jul 31, 2018
Start date
Jul 1, 2017
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Nov 8, 2023

Study contacts

Audrius Dulskas, MD, PhD
principal investigator · National Cancer Institute (NCI)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion